long intergenic non-protein coding RNA 2752Genealiases: []
Q-omics provides the consensus-scored LINC02752 profile across patient tissues and cancer cell-line models. LINC02752 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LINC02752 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, LINC02752 RNA expression shows 10,783 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight SKCM, and LUAD as cancer lineages where LINC02752 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02752 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02752 survival associations across molecular data types. LINC02752 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02752 RNA expression–survival associations across cancer types. High LINC02752 expression shows unfavorable associations in UCEC, ESCA and KICH, but favorable associations in SKCM, LUAD and LGG. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for LINC02752 RNA expression.
This table summarizes LINC02752 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02752. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02752 shows lower tumor expression in LUAD, KICH, UCEC, LUSC and COAD and higher tumor expression in KIRC. The LUAD box plot shows higher LINC02752 RNA expression in normal versus tumor tissue (log2 FC = −0.256, t-test p < 0.001).
This table shows molecular features associated with LINC02752 in patient tissues and cancer cell lines. In patient samples, LINC02752 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
